CJC-1295: A Long-Acting GHRH Analog With Real Pharmacology and No Efficacy Trial

The short version

CJC-1295 is a lab-made version of growth-hormone-releasing hormone (GHRH), the natural signal that tells the pituitary gland to release growth hormone. Four small chemical changes make it resist breakdown in the body, and in its long-acting 'DAC' form, it also attaches to a blood protein called albumin, which lets a single dose keep growth hormone and a related hormone, IGF-1, elevated for days rather than minutes.

What is actually known about it in people comes from a handful of small studies from the mid-2000s — fewer than 40 total volunteers across the published human research — showing that it does raise growth hormone and IGF-1 as designed. What is not known: whether raising those hormones this way produces any of the muscle, fat-loss, sleep, or anti-aging outcomes commonly claimed for it, because no controlled human trial has tested any of them. CJC-1295 is not approved for human use anywhere, and it is sold only as a research chemical.

What it is

CJC-1295 is a synthetic analog of the first 29 amino acids of human growth-hormone-releasing hormone, hGRF(1-29), carrying four substitutions — D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27 — that stabilize its alpha-helical structure and block the enzymatic cleavage, deamidation, and oxidation that destroy native GHRH within minutes.

Two distinct forms circulate under the CJC-1295 name and are frequently confused with each other. The 'DAC' (Drug Affinity Complex) form adds a maleimidopropionyl linker at the C-terminus that forms a covalent bond with a free thiol on circulating serum albumin — effectively hitching the peptide to a blood protein with a multi-day lifespan of its own. The 'no-DAC' form (sometimes sold as 'Modified GRF 1-29') keeps the four stabilizing substitutions but skips the albumin-binding chemistry, and is correspondingly short-acting — active for minutes to hours rather than days. Because these two forms behave so differently in the body, knowing which one is actually in a vial matters more than most marketing acknowledges.

How it works

CJC-1295 binds the growth-hormone-releasing hormone receptor (GHRHR) on somatotroph cells in the anterior pituitary, activating a Gs-protein/cAMP/PKA signaling cascade that stimulates both the synthesis and the pulsatile release of growth hormone. Growth hormone released this way then acts on the liver to raise circulating IGF-1, the hormone most directly responsible for GH's anabolic effects on muscle and connective tissue.

A notable and somewhat reassuring detail from the human data: continuous GHRH-receptor stimulation with CJC-1295 does not appear to flatten the body's normal pulsatile pattern of GH release into one long plateau. A human dosing study found the frequency and magnitude of GH pulses were preserved even under sustained CJC-1295 exposure ^[5] — the drug appears to raise the baseline and amplify the pulses rather than replacing pulsatile secretion with constant secretion. Whether that distinction matters clinically is not established; it is simply what the pharmacology shows so far.

What the research shows

Framing review. A 2025 review in a major endocrinology journal synthesizes the pharmacology of GHRH and its synthetic analogs as a class — including CJC-1295, sermorelin, and tesamorelin — describing receptor signaling and the general therapeutic landscape. It is a review, not new primary data, and should be read as context rather than fresh evidence for CJC-1295 specifically ^[1].

Analytical identification, not efficacy. A 2010 study used high-resolution mass spectrometry to confirm that a seized, unlabeled 'GHRH' preparation in an anti-doping context actually contained CJC-1295 ^[2]. This is chemistry, not pharmacology — it establishes that the compound circulates in the black market under vague labels, and nothing about whether it works.

Serum proteome study, n=11. In eleven healthy young men, CJC-1295 shifted several serum proteins, and one signal tracked linearly with IGF-1 levels ^[3]. A genuinely small study exploring candidate biomarkers, not a clinical outcome trial.

The core pharmacokinetic data. In healthy adults aged 21 to 61, single subcutaneous doses of 30 or 60 micrograms per kilogram produced dose-dependent 2- to 10-fold increases in mean plasma growth hormone lasting six days or more, and 1.5- to 3-fold increases in IGF-1 lasting nine to eleven days. After repeated dosing, IGF-1 stayed above baseline for up to 28 days, and the estimated half-life of CJC-1295 itself was 5.8 to 8.1 days ^[4]. This is the single most-cited human dataset for the compound — a dose-response pharmacokinetic study, not an efficacy trial for any downstream outcome.

Pulsatility preserved. A single 60 or 90 microgram/kg dose in healthy men aged 20 to 40 raised trough GH roughly 7.5-fold and both mean GH and IGF-1 substantially one week later, while leaving the underlying pattern of pulsatile GH secretion intact ^[5]. Read together, ^[4] and ^[5] are the entirety of the controlled human pharmacology base for CJC-1295 — real, reproducible, and narrow in scope.

Reported effects, cautions & safety

The claims made for CJC-1295 in research-use communities go well beyond anything the studies above measured. What follows is anecdotal, not clinical evidence — self-reported experience from online forums and consumer guides, none of it collected under controlled conditions or attached to a verified dose.

The most consistently reported benefit is deeper, more restful sleep, often described as the first effect noticed. Faster training recovery, gradual fat loss (usually reported after three to six weeks, alongside diet and exercise), a leaner appearance, modestly increased daytime energy, and sharper focus follow in roughly that order of frequency.

On the adverse side, water retention and facial or hand puffiness are the most common complaint, attributed by the community to the long-acting DAC form specifically. Tingling or numbness in the hands (likened to mild carpal tunnel), minor injection-site irritation, flushing or a brief head-rush after injecting, fatigue, headache, and — mainly when CJC-1295 is stacked with ipamorelin — increased appetite round out the more frequent reports. A smaller number of accounts describe elevated blood sugar with sustained use.

The cited safety concerns are mechanistic, not drawn from any dedicated CJC-1295 safety trial, because none exists. CJC-1295 elevates IGF-1, a mitogen linked in population studies to a modestly increased cancer risk, giving anyone with a personal or family history of cancer a real mechanism-based reason for caution. Growth hormone's sodium- and water-retaining action gives the reported bloating and nerve-compression effects a plausible physiological basis, and its glucose-sparing action is a legitimate concern for anyone with diabetes or insulin resistance ^[4]. A current pharmacology review flags immunogenicity considerations for long-acting, albumin-binding GHRH analogs like the DAC form ^[1], and the original long-acting CJC-1295 DAC development program was discontinued, with a patient death during that era frequently cited alongside the halted trial — though the public record does not establish that CJC-1295 caused it. CJC-1295 is prohibited in sport at all times and is not approved for human use by any regulator.

Where it fits in the evidence hierarchy

Among the five compounds on this desk, CJC-1295 occupies an odd middle position: its core human pharmacology — that it reliably raises GH and IGF-1 for days at a time ^[4][5] — is more solidly established in people than KPV's mechanism (rodent-only) or, arguably, than ipamorelin's clinical case (a failed trial ^[8]). But CJC-1295 has never been tested for any actual outcome in a controlled human trial — no muscle, fat-loss, sleep, or anti-aging endpoint has been measured against placebo in people. Semaglutide and, to a lesser extent, retatrutide have exactly that kind of outcome data; CJC-1295 does not. The honest summary is that CJC-1295's pharmacology is well characterized and its efficacy for any of its marketed uses is simply untested. See the comparison page for how all five stack up side by side.